Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / INM - InMed completes enrollment to test cannabinol cream to treat epidermolysis bullosa results from trial in early Q3

INM - InMed completes enrollment to test cannabinol cream to treat epidermolysis bullosa results from trial in early Q3

InMed Pharmaceuticals Inc.

2023-03-28 09:12:37 ET

  • InMed Pharma ( NASDAQ: INM ) said it had completed enrollment for its Phase 2 trial testing investigational drug, INM-755, a cannabinol cream to treat epidermolysis bullosa (EB), a rare genetic skin disease.
  • The company said results from the Phase 2 study of the cream were expected to be released on early Q3.
  • The trial will test the safety and efficacy in treating symptoms of itch, pain, and wound healing in patients with epidermolysis bullosa .

For further details see:

InMed completes enrollment to test cannabinol cream to treat epidermolysis bullosa, results from trial in early Q3
Stock Information
Company Name: InMed Pharmaceuticals Inc.
Stock Symbol: INM
Market: NASDAQ
Website: inmedpharma.com
Menu
INM INM Quote INM Short INM News INM Articles INM Message Board
Get INM Alerts

News, Short Squeeze, Breakout and More Instantly...